Preventing autoimmunity protects against the development of hypertension and renal injury

Keisa W. Mathis, Kedra Wallace, Elizabeth R. Flynn, Christine Maric-Bilkan, Babbette LaMarca, Michael J. Ryan

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Several studies suggest a link between autoimmunity and essential hypertension in humans. However, whether autoimmunity can drive the development of hypertension remains unclear. The autoimmune disease systemic lupus erythematosus is characterized by autoantibody production, and the prevalence of hypertension is increased markedly in this patient population compared with normal healthy women. We hypothesized that preventing the development of autoimmunity would prevent the development of hypertension in a mouse model of lupus. Female lupus (NZBWF1) and control mice (NZW) were treated weekly with anti-CD20 or immunoglobulin G antibodies (both 10 mg/kg, IV) starting at 20 weeks of age for 14 weeks. Anti-CD20 therapy markedly attenuated lupus disease progression as evidenced by reduced CD45R+ B cells and lower double-stranded DNA autoantibody activity. In addition, renal injury in the form of urinary albumin, glomerulosclerosis, and tubulointerstitial fibrosis, as well as tubular injury (indicated by renal cortical expression of neutrophil gelatinase-associated lipocalin) was prevented by anti-CD20 therapy in lupus mice. Finally, lupus mice treated with anti-CD20 antibody did not develop hypertension. The protection against the development of hypertension was associated with lower renal cortical tumor necrosis factor-a expression, a cytokine that has been previously reported by us to contribute to the hypertension in this model, as well as renal cortical monocyte chemoattractant protein-1 expression and circulating T cells. These data suggest that the development of autoimmunity and the resultant increase in renal inflammation are an important underlying factor in the prevalent hypertension that occurs during systemic lupus erythematosus.

Original languageEnglish
Pages (from-to)792-800
Number of pages9
JournalHypertension
Volume64
Issue number4
DOIs
StatePublished - 1 Jan 2014

Fingerprint

Renal Hypertension
Autoimmunity
Hypertension
Wounds and Injuries
Kidney
Systemic Lupus Erythematosus
Autoantibodies
Chemokine CCL2
Autoimmune Diseases
Disease Progression
Anti-Idiotypic Antibodies
Albumins
Fibrosis
B-Lymphocytes
Tumor Necrosis Factor-alpha
Immunoglobulin G
Cytokines
Inflammation
T-Lymphocytes
Antibodies

Keywords

  • Autoantibodies
  • B-lymphocytes
  • Pressure
  • T-lymphocytes

Cite this

Mathis, Keisa W. ; Wallace, Kedra ; Flynn, Elizabeth R. ; Maric-Bilkan, Christine ; LaMarca, Babbette ; Ryan, Michael J. / Preventing autoimmunity protects against the development of hypertension and renal injury. In: Hypertension. 2014 ; Vol. 64, No. 4. pp. 792-800.
@article{13cc8ebb39514a4e869e27ff69030c40,
title = "Preventing autoimmunity protects against the development of hypertension and renal injury",
abstract = "Several studies suggest a link between autoimmunity and essential hypertension in humans. However, whether autoimmunity can drive the development of hypertension remains unclear. The autoimmune disease systemic lupus erythematosus is characterized by autoantibody production, and the prevalence of hypertension is increased markedly in this patient population compared with normal healthy women. We hypothesized that preventing the development of autoimmunity would prevent the development of hypertension in a mouse model of lupus. Female lupus (NZBWF1) and control mice (NZW) were treated weekly with anti-CD20 or immunoglobulin G antibodies (both 10 mg/kg, IV) starting at 20 weeks of age for 14 weeks. Anti-CD20 therapy markedly attenuated lupus disease progression as evidenced by reduced CD45R+ B cells and lower double-stranded DNA autoantibody activity. In addition, renal injury in the form of urinary albumin, glomerulosclerosis, and tubulointerstitial fibrosis, as well as tubular injury (indicated by renal cortical expression of neutrophil gelatinase-associated lipocalin) was prevented by anti-CD20 therapy in lupus mice. Finally, lupus mice treated with anti-CD20 antibody did not develop hypertension. The protection against the development of hypertension was associated with lower renal cortical tumor necrosis factor-a expression, a cytokine that has been previously reported by us to contribute to the hypertension in this model, as well as renal cortical monocyte chemoattractant protein-1 expression and circulating T cells. These data suggest that the development of autoimmunity and the resultant increase in renal inflammation are an important underlying factor in the prevalent hypertension that occurs during systemic lupus erythematosus.",
keywords = "Autoantibodies, B-lymphocytes, Pressure, T-lymphocytes",
author = "Mathis, {Keisa W.} and Kedra Wallace and Flynn, {Elizabeth R.} and Christine Maric-Bilkan and Babbette LaMarca and Ryan, {Michael J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.114.04006",
language = "English",
volume = "64",
pages = "792--800",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "4",

}

Preventing autoimmunity protects against the development of hypertension and renal injury. / Mathis, Keisa W.; Wallace, Kedra; Flynn, Elizabeth R.; Maric-Bilkan, Christine; LaMarca, Babbette; Ryan, Michael J.

In: Hypertension, Vol. 64, No. 4, 01.01.2014, p. 792-800.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preventing autoimmunity protects against the development of hypertension and renal injury

AU - Mathis, Keisa W.

AU - Wallace, Kedra

AU - Flynn, Elizabeth R.

AU - Maric-Bilkan, Christine

AU - LaMarca, Babbette

AU - Ryan, Michael J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Several studies suggest a link between autoimmunity and essential hypertension in humans. However, whether autoimmunity can drive the development of hypertension remains unclear. The autoimmune disease systemic lupus erythematosus is characterized by autoantibody production, and the prevalence of hypertension is increased markedly in this patient population compared with normal healthy women. We hypothesized that preventing the development of autoimmunity would prevent the development of hypertension in a mouse model of lupus. Female lupus (NZBWF1) and control mice (NZW) were treated weekly with anti-CD20 or immunoglobulin G antibodies (both 10 mg/kg, IV) starting at 20 weeks of age for 14 weeks. Anti-CD20 therapy markedly attenuated lupus disease progression as evidenced by reduced CD45R+ B cells and lower double-stranded DNA autoantibody activity. In addition, renal injury in the form of urinary albumin, glomerulosclerosis, and tubulointerstitial fibrosis, as well as tubular injury (indicated by renal cortical expression of neutrophil gelatinase-associated lipocalin) was prevented by anti-CD20 therapy in lupus mice. Finally, lupus mice treated with anti-CD20 antibody did not develop hypertension. The protection against the development of hypertension was associated with lower renal cortical tumor necrosis factor-a expression, a cytokine that has been previously reported by us to contribute to the hypertension in this model, as well as renal cortical monocyte chemoattractant protein-1 expression and circulating T cells. These data suggest that the development of autoimmunity and the resultant increase in renal inflammation are an important underlying factor in the prevalent hypertension that occurs during systemic lupus erythematosus.

AB - Several studies suggest a link between autoimmunity and essential hypertension in humans. However, whether autoimmunity can drive the development of hypertension remains unclear. The autoimmune disease systemic lupus erythematosus is characterized by autoantibody production, and the prevalence of hypertension is increased markedly in this patient population compared with normal healthy women. We hypothesized that preventing the development of autoimmunity would prevent the development of hypertension in a mouse model of lupus. Female lupus (NZBWF1) and control mice (NZW) were treated weekly with anti-CD20 or immunoglobulin G antibodies (both 10 mg/kg, IV) starting at 20 weeks of age for 14 weeks. Anti-CD20 therapy markedly attenuated lupus disease progression as evidenced by reduced CD45R+ B cells and lower double-stranded DNA autoantibody activity. In addition, renal injury in the form of urinary albumin, glomerulosclerosis, and tubulointerstitial fibrosis, as well as tubular injury (indicated by renal cortical expression of neutrophil gelatinase-associated lipocalin) was prevented by anti-CD20 therapy in lupus mice. Finally, lupus mice treated with anti-CD20 antibody did not develop hypertension. The protection against the development of hypertension was associated with lower renal cortical tumor necrosis factor-a expression, a cytokine that has been previously reported by us to contribute to the hypertension in this model, as well as renal cortical monocyte chemoattractant protein-1 expression and circulating T cells. These data suggest that the development of autoimmunity and the resultant increase in renal inflammation are an important underlying factor in the prevalent hypertension that occurs during systemic lupus erythematosus.

KW - Autoantibodies

KW - B-lymphocytes

KW - Pressure

KW - T-lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84914664859&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.114.04006

DO - 10.1161/HYPERTENSIONAHA.114.04006

M3 - Article

C2 - 25024282

AN - SCOPUS:84914664859

VL - 64

SP - 792

EP - 800

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -